Table 1 Comparisons of characteristics between chemotherapy group and control group in original 12,334 HR-positive, Her-2-negative, pT1b-c/N0–1/M0 ILC patients
Control (n = 10,549) | Chemotherapy (n = 1785) | Statistical value | P | bias | t-test for bias | P | ||
|---|---|---|---|---|---|---|---|---|
Age (years) | < 40 | 59 (0.56%) | 47 (2.63%) | χ2 = 576.457 | 0.001 | −62.1 | −24.37 | 0.001 |
40–49 | 1088 (10.31%) | 392 (21.96%) | ||||||
50–59 | 2316 (21.95%) | 605 (33.89%) | ||||||
60–69 | 3896 (36.93%) | 557 (31.20%) | ||||||
70–79 | 3190 (30.24%) | 184 (10.31%) | ||||||
Race | Black | 868 (8.23%) | 174 (9.75%) | χ2 = 4.627 | 0.099 | −4.6 | −1.81 | 0.071 |
White | 8966 (84.99%) | 1495 (83.75%) | ||||||
Other | 715 (6.78%)) | 116 (6.50%)) | ||||||
Tumor | Ib | 3455 (32.75%) | 374 (20.95%) | χ2 = 99.294 | 0.001 | 26.9 | 10.00 | 0.001 |
Ic | 7094 (67.25%) | 1411 (79.05%) | ||||||
LN | N0 | 9308 (88.24%) | 895 (50.14%) | χ2 = 1.6e+ 03 | 0.001 | 90.6 | 42.10 | 0.001 |
N1 | 1241 (11.76%) | 890 (49.86%) | ||||||
Grade | I | 3618 (34.30%) | 430 (24.09%) | z = −10.373 | 0.001 | 27.6 | 10.87 | 0.001 |
II | 6472 (61.35%) | 1188 (66.55%) | ||||||
III | 459 (4.35%) | 167 (9.36%) | ||||||
Radiotherapy | No | 4774 (45.26%) | 883 (49.47%) | χ2 = 10.910 | 0.001 | −8.4 | −3.30 | 0.001 |
Yes | 5775 (54.74%) | 902 (50.53%) | ||||||
Surgery | No surgery | 177 (1.68%) | 36 (2.02%) | χ2 = 190.161 | 0.001 | 31.5 | 12.61 | 0.001 |
BCS | 6777 (64.24%) | 842 (47.17%) | ||||||
Mastectomy | 3595 (34.08%) | 907 (50.81%) |